Comparison of two xenografts in maxillary sinus augmentation

Assessment of histological, clinical and radiographic outcome?s of maxillary sinus augmentation using two different xenograft materials: split mouth clinical trial

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20211122053149N1

Enrollment

Registered

2021-12-25

Start date

2021-11-06

Completion date

Unknown

Last updated

2022-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Maxillary sinus augmentation. Atrophy of edentulous alveolar ridge

Interventions

Intervention 1: Intervention group: Lateral window maxillary sinus augmentation using Bone+ (Novateb Pars, Iran) at one side of the participant s mouth. Intervention 2: Control group: Lateral window m

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: > 18 years Good general health Inadequate bone for a standard implant (< 5 mm residual alveolar bone height to the maxillary sinus floor) Absence of infection or periapical lesion

Exclusion criteria

Exclusion criteria: Smoking O'Leary plaque index > 20% Allergy to the material used in the study Pregnancy/ lactation Uncontrolled periodontal disease Systemic disease or intake of any medication History of sinusitis or any pathologic condition in the sinus

Design outcomes

Primary

Measure	Time frame
Sinus augmentation volume. Timepoint: 6 months following maxillary sinus augmentation. Method of measurement: Computed tomography.	—

Secondary

Measure	Time frame
New bone formation. Timepoint: 6 months after intervention. Method of measurement: Histologic evaluation.;Residual material. Timepoint: 6 months after intervention. Method of measurement: Histologic evaluation.;Inflammation rate. Timepoint: 6 months after intervention. Method of measurement: Histologic evaluation.;Type of inflammation. Timepoint: 6 months after intervention. Method of measurement: Histologic evaluation.;Normal connective tissue. Timepoint: 6 months after intervention. Method of measurement: Histologic evaluation.;Granulation tissue. Timepoint: 6 months after intervention. Method of measurement: Histologic evaluation.;Necrotic tissue. Timepoint: 6 months after intervention. Method of measurement: Histologic evaluation.;Giant cell. Timepoint: 6 months after intervention. Method of measurement: Histologic evaluation.	—

Measure

Time frame

New bone formation. Timepoint: 6 months after intervention. Method of measurement: Histologic evaluation.;Residual material. Timepoint: 6 months after intervention. Method of measurement: Histologic evaluation.;Inflammation rate. Timepoint: 6 months after intervention. Method of measurement: Histologic evaluation.;Type of inflammation. Timepoint: 6 months after intervention. Method of measurement: Histologic evaluation.;Normal connective tissue. Timepoint: 6 months after intervention. Method of measurement: Histologic evaluation.;Granulation tissue. Timepoint: 6 months after intervention. Method of measurement: Histologic evaluation.;Necrotic tissue. Timepoint: 6 months after intervention. Method of measurement: Histologic evaluation.;Giant cell. Timepoint: 6 months after intervention. Method of measurement: Histologic evaluation.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAnahita Moscowchi

Shahid Beheshti University of Medical Sciences

a.moscowchi@gmail.com+98 21 2240 3075

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026